501 related articles for article (PubMed ID: 29454592)
1. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
[TBL] [Abstract][Full Text] [Related]
2. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
Liapikou A; Dimakou K; Toumbis M
Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
[TBL] [Abstract][Full Text] [Related]
3. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
5. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.
Torres A; Rubinstein E; Corey GR; Stryjewski ME; Barriere SL
J Antimicrob Chemother; 2014 Apr; 69(4):1119-26. PubMed ID: 24398339
[TBL] [Abstract][Full Text] [Related]
7. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
Laohavaleeson S; Barriere SL; Nicolau DP; Kuti JL
Pharmacotherapy; 2008 Dec; 28(12):1471-82. PubMed ID: 19025428
[TBL] [Abstract][Full Text] [Related]
9. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Daniel Mullins C; Kuznik A; Shaya FT; Obeidat NA; Levine AR; Liu LZ; Wong W
Clin Ther; 2006 Aug; 28(8):1184-1198. PubMed ID: 16982296
[TBL] [Abstract][Full Text] [Related]
11. Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies.
Wilson SE; Graham DR; Wang W; Bruss JB; Castaneda-Ruiz B
Infect Dis Ther; 2017 Sep; 6(3):413-422. PubMed ID: 28695347
[TBL] [Abstract][Full Text] [Related]
12. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
13. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D
Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453
[TBL] [Abstract][Full Text] [Related]
14. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan.
Lin PC; Wang BC; Kim R; Magyar A; Lai CC; Yang YW; Huang YC
J Microbiol Immunol Infect; 2016 Feb; 49(1):46-51. PubMed ID: 26454421
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
McMullen AR; Lainhart W; Wallace MA; Shupe A; Burnham CD
Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
[TBL] [Abstract][Full Text] [Related]
16. Telavancin: a review of its use in patients with nosocomial pneumonia.
Scott LJ
Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
[TBL] [Abstract][Full Text] [Related]
17. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
Collins CD; Schwemm AK
Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
[TBL] [Abstract][Full Text] [Related]
18. The role of telavancin in the treatment of MRSA infections in hospital.
Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
[TBL] [Abstract][Full Text] [Related]
19. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
Adamantia L; Antoni T
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
